PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.72%
EBIT growth of 32.72% while GNPX is zero. Bruce Berkowitz would see if small gains can be scaled further.
-21.99%
Negative operating income growth while GNPX is at 0.00%. Joel Greenblatt would press for urgent turnaround measures.
32.68%
Net income growth of 32.68% while GNPX is zero. Bruce Berkowitz would see if small gains can accelerate into a larger gap.
32.51%
EPS growth of 32.51% while GNPX is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
32.51%
Diluted EPS growth of 32.51% while GNPX is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
Negative OCF growth while GNPX is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-20.05%
Negative FCF growth while GNPX is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-102666.73%
Negative 10Y OCF/share CAGR while GNPX stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-29000.87%
Negative 5Y OCF/share CAGR while GNPX is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
0.57%
3Y OCF/share CAGR of 0.57% while GNPX is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-765363.95%
Negative 10Y net income/share CAGR while GNPX is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-27613.67%
Negative 5Y net income/share CAGR while GNPX is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-208.91%
Negative 3Y CAGR while GNPX is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
82516.86%
Equity/share CAGR of 82516.86% while GNPX is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
5226.69%
Equity/share CAGR of 5226.69% while GNPX is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
1660.30%
Equity/share CAGR of 1660.30% while GNPX is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.20%
Negative asset growth while GNPX invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-8.72%
We have a declining book value while GNPX shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-32.96%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
44.99%
R&D growth of 44.99% while GNPX is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
-4.08%
We cut SG&A while GNPX invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.